[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643715":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":29,"collaborators":10,"id":33,"slug":34,"hasResults":35,"nctId":36,"briefTitle":37,"officialTitle":38,"acronym":10,"eligibilityCriteria":39,"healthyVolunteers":35,"sex":40,"minAge":41,"maxAge":42,"enrollmentInfo":43,"targetDuration":10,"studyType":46,"phases":10,"briefSummary":47,"conditions":48,"keywords":10,"overallStatus":50,"whyStopped":10,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":10},{"fullName":5,"class":6},"First Affiliated Hospital, Sun Yat-Sen University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"GnRH\u002FHRT",null,"PCE patients with GnRH agonist pretreatment combined with hormone replacement therapy (GnRH-HRT) endometrial preparation",[13],"Drug: GnRH agonist plus estrogen-progesterone for endometrial preparation",{"label":15,"type":10,"description":16,"interventionNames":17},"non-GnRH-HRT","PCE patients with non-GnRH-HRT regimens (HRT alone or natural cycle, NC),",[18],"Drug: Conventional estrogen-progesterone artificial cycle for endometrial preparation",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Conventional estrogen-progesterone artificial cycle for endometrial preparation","No GnRH-a down-regulation. Oral estrogen is initiated directly on early menstrual cycle, followed by progesterone transformation to prepare endometrium for FET in patients with persistent chronic endometritis.",[15],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"GnRH agonist plus estrogen-progesterone for endometrial preparation","Long-acting GnRH agonist is administered on day 2-3 of menstruation for pituitary down-regulation. After satisfactory hormonal suppression, sequential oral estrogen and progesterone are used to prepare endometrium before frozen embryo transfer in patients with persistent chronic endometritis.",[9],{"type":30,"investigatorFullName":31,"investigatorTitle":32,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Guoxia Yang","Associate Chief Physician, Reproductive Medicine Department","100643715","gnrh-agonist-pretreatment-in-persistent-chronic-endometritis-undergoing-fet-100643715",false,"NCT07642700","GnRH Agonist Pretreatment in Persistent Chronic Endometritis Undergoing FET","Association of GnRH Agonist Pretreatment With Pregnancy Outcomes in Women With Persistent Chronic Endometritis Undergoing Frozen Embryo Transfer","Inclusion Criteria:\n\n* Aged 20-40 years; confirmed persistent chronic endometritis (PCE) via hysteroscopy plus CD138 immunohistochemistry, defined as positive endometrial pathology after two-course antibiotic treatment for CE.\n* Frozen-thawed embryo transfer (FET) with available transferable cleavage-stage or blastocyst embryos from IVF\u002FICSI cycles.\n* No acute pelvic infection at enrollment; ≥1 month elapsed after completion of last antibiotic therapy for endometritis.\n* Normal uterine cavity except for inflammatory changes of PCE; no severe uterine malformation or severe intrauterine adhesion requiring surgical intervention.\n* Voluntarily sign informed consent and complete full follow-up of pregnancy outcomes\n\nExclusion Criteria:\n\n* History of pelvic tuberculosis, intrauterine adhesions, submucous uterine myoma or endometrial polyp before FET\n* Uncontrolled systemic endocrine disorders, autoimmune diseases (APS, SLE), severe hepatic\u002Frenal\u002Fcardiopulmonary dysfunction.\n* Known allergy to GnRH agonist for down-regulation regimen; prior long-acting GnRH-a intolerance.\n* Recent use of immunosuppressant, long-term glucocorticoid or drugs interfering endometrial development within 3 months before enrollment.\n* Lost to follow-up or plan to abandon embryo transfer after enrollment.","FEMALE","20 Years","40 Years",{"count":44,"type":45},150,"ESTIMATED","OBSERVATIONAL","Women with PCE represent a treatment-resistant phenotype in whom the endometrial inflammatory and immune status remains abnormal despite antibiotic therapy. GnRH agonist pretreatment may be most beneficial in endometrial phenotypes marked by persistent or residual inflammatory impairment rather than in all frozen embryo transfer populations.We therefore conducted a single-center prospective cohort study to investigate whether GnRH-HRT, compared with non-GnRH-based preparations, improve clinical pregnancy and live birth in women with PCE undergoing FET,",[49],"Chronic Endometritis","NOT_YET_RECRUITING","2026-06-10",{"date":53,"type":54},"2026-06-11","ACTUAL",{"date":56,"type":45},"2026-06-01",{"date":58,"type":45},"2028-06-01",{"name":31,"class":6}]